G
Goteborgbank
Guest
Giuen Wellness Merchant Press
New Report Predicts that Novartis' Diovan, Glivec/Gleevec and Zelmac/
Zelnorm will Continue to Show Healthy Sales Growth
Saturday, August 11, 2007
Aug. 3, 2007 (M2 Communications Ltd. delivered by Newstex) --
Research and Markets (http://www.researchandmarkets.com/reports/
c64757) has announced the addition of Novartis: Performance, Products,
Pipeline and Potential to their offering
Pharmaceutical company intelligence reports provide a full review of
the company's activities together with five-year sales forecasts for
its key products. The company's financial performance is covered in-
depth, from its latest results to a complete analysis of
itscccccccclatest full fiscal year and an outlook for the future. A
section on company strategy covers mergers, acquisitions and
divestitures, key agreements, products and R&D. An overview of key
products and R&D is followed by a comprehensive review of the
company's product portfolio and research and development pipeline by
therapeutic area. In addition, supplementary appendices provide more
in-depth information on financials, agreements and corporate events.
Following the merger of Ciba and Sandoz, the spin-off of the
Agribusiness sector and the sale of the remaining activities of the
Industry division, Novartis has become a leading company in the life
sciences field and has operations in approximately 140 countries
worldwide. Novartis is currently organised into the four divisions of
Pharmaceuticals, Consumer Health, Sandoz and Vaccines &
Diagnostics, created following the acquisition of Chiron Corporation.
Within Pharmaceuticals, the company's current growth drivers include
Diovan (valsartan), Glivec/Gleevec (imatinib), Femara (letrozole) and
Zometa (zoledronate).
Novartis' current pharma growth drivers together account for
approximately 38 per cent of total pharma sales, and we predict that
Diovan, Glivec/Gleevec and Zelmac/Zelnorm will continue to demonstrate
substantial sales growth within the medium term. In addition, the
recent launch and approval of a selection of products which include
Exjade (deferasirox), Prexige (lumiracoxib), Xolair (omalizumab),
Exforge (valsartan+amlodipine), Lucentis (ranibizumab) and Tekturna
(aliskiren), should offset the decline in sales of a number of
Novartis' strategic products. However, this confidence is tempered by
the recent setbacks to the fortunes of Zelnorm/Zelmac (tegaserod) and
Tekturna.
As a research-intensive company which has benefited from the Chiron
acquisition, Novartis has a strong pharma pipeline with a total of 138
compounds under development. Of particular note are: Galvus
(vildagliptin), filed for Type II diabetes in the US and the EU; and
fingolimod under Phase III development for multiple sclerosis.
However, Novartis still faces some hurdles since the approvable letter
for Galvus has allowed Merck's Januvia a head start in the important
US market.
Novartis' major company strategy is based on innovation and achieving
a leading position in the healthcare sector. To this end, in 2005, the
Pharmaceuticals division further expanded its research operations and
this process continued in 2006. Pharmaceuticals remains Novartis'
largest and most profitable business, with the Cardiovascular and
Oncology franchises continuing as the leading therapeutic areas.
Chiron's pharmaceutical operations are being integrated into the
Pharmaceuticals division.
In the light of government cost containment measures, Novartis intends
to develop new growth platforms such as vaccines (which will reduce
costs through disease prevention) and expand its generic business (so
capitalising on governments' promotion of generics).
This new strategic analysis report Novartis: Performance, Products,
Pipeline and Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts
of key products. The report is updated on a quarterly basis. Buyers of
the web edition receive quarterly reports for a year. Buyers of the
print/pdf editions receive the latest version. All formats are the
same price.
EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position,
company strategy, product and pipeline analysis.
THERAPEUTIC AREA FOCUS
Key product analysis and forecasting
Cardiovascular and Metabolism
Diovan/Co-Diovan (valsartan)
Exforge (amlodipine+valsartan)
Lescol (fluvastatin)
Lotrel (amlodipine+benazepril)
Tekturna (aliskiren)
Oncology/Haematology
Exjade (deferasirox)
Femara (letrozole)
Glivec/Gleevec (imatinib)
Sandostatin (octreotide)
Zometa/Aclasta (zoledronic acid)
Neuroscience
Comtan (entacapone)
Exelon (rivastigmine)
Ritalin/Focalin (methylphenidate)
Stalevo (entacapone)
Trileptal (oxcarbazepine)
Arthritis/Bone
Miacalcic/Miacalcin (synthetic salmon calcitonin)
Prexige (lumiracoxib)
Voltaren/Cataflam (diclofenac sodium)
Gastrointestinal
Zelnorm/Zelmac (tegaserod)
Respiratory/Dermatology
Elidel (pimecrolimus)
Foradil (formoterol fumarate)
Lamisil (terbinafine)
Xolair (omalizumab)
Transplantation/Immunology
Certican (everolimus)
Sandimmun/Neoral (ciclosporin)
Infectious Diseases
Famvir/Denavir (famciclovir)
Sebivo/Tyzeka (telbivudine)
Ophthalmics
Lucentis (ranibizumab)
Visudyne (verteporfin)
OPERATIONAL DATA
A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Infrastructure
Subsidiaries
For more information visit http://www.researchandmarkets.com/reports/c64757
Source: Espicom Business Intelligence
(Comments on this story may be sent to tww.feedback@m2.com)
Newstex ID: MCOM-0001-18828037
Delivered by Newstex LLC
via theFinancials.com
Giuen Media
Advertising Agency
Sales and Promotion
http://giuen.wordpress.com
Associate Website
CWM Online Blog
http://groups.google.com/group/cwm-celebrities
Celebrities Fitness Systems
http://vibe1.redcarpet1.hop.clickbank.net/?tid=MASTER
Online Advertising and Marketing
http://www.adbrite.com/mb/commerce/purchase_form.php?opid=377909&afsid=1
TRADEKEY.COM - Your Key To Global Trade!
A B2B Marketplace for latest products from global Exporters,
Suppliers, Manufacturers and Distributors.
New Report Predicts that Novartis' Diovan, Glivec/Gleevec and Zelmac/
Zelnorm will Continue to Show Healthy Sales Growth
Saturday, August 11, 2007
Aug. 3, 2007 (M2 Communications Ltd. delivered by Newstex) --
Research and Markets (http://www.researchandmarkets.com/reports/
c64757) has announced the addition of Novartis: Performance, Products,
Pipeline and Potential to their offering
Pharmaceutical company intelligence reports provide a full review of
the company's activities together with five-year sales forecasts for
its key products. The company's financial performance is covered in-
depth, from its latest results to a complete analysis of
itscccccccclatest full fiscal year and an outlook for the future. A
section on company strategy covers mergers, acquisitions and
divestitures, key agreements, products and R&D. An overview of key
products and R&D is followed by a comprehensive review of the
company's product portfolio and research and development pipeline by
therapeutic area. In addition, supplementary appendices provide more
in-depth information on financials, agreements and corporate events.
Following the merger of Ciba and Sandoz, the spin-off of the
Agribusiness sector and the sale of the remaining activities of the
Industry division, Novartis has become a leading company in the life
sciences field and has operations in approximately 140 countries
worldwide. Novartis is currently organised into the four divisions of
Pharmaceuticals, Consumer Health, Sandoz and Vaccines &
Diagnostics, created following the acquisition of Chiron Corporation.
Within Pharmaceuticals, the company's current growth drivers include
Diovan (valsartan), Glivec/Gleevec (imatinib), Femara (letrozole) and
Zometa (zoledronate).
Novartis' current pharma growth drivers together account for
approximately 38 per cent of total pharma sales, and we predict that
Diovan, Glivec/Gleevec and Zelmac/Zelnorm will continue to demonstrate
substantial sales growth within the medium term. In addition, the
recent launch and approval of a selection of products which include
Exjade (deferasirox), Prexige (lumiracoxib), Xolair (omalizumab),
Exforge (valsartan+amlodipine), Lucentis (ranibizumab) and Tekturna
(aliskiren), should offset the decline in sales of a number of
Novartis' strategic products. However, this confidence is tempered by
the recent setbacks to the fortunes of Zelnorm/Zelmac (tegaserod) and
Tekturna.
As a research-intensive company which has benefited from the Chiron
acquisition, Novartis has a strong pharma pipeline with a total of 138
compounds under development. Of particular note are: Galvus
(vildagliptin), filed for Type II diabetes in the US and the EU; and
fingolimod under Phase III development for multiple sclerosis.
However, Novartis still faces some hurdles since the approvable letter
for Galvus has allowed Merck's Januvia a head start in the important
US market.
Novartis' major company strategy is based on innovation and achieving
a leading position in the healthcare sector. To this end, in 2005, the
Pharmaceuticals division further expanded its research operations and
this process continued in 2006. Pharmaceuticals remains Novartis'
largest and most profitable business, with the Cardiovascular and
Oncology franchises continuing as the leading therapeutic areas.
Chiron's pharmaceutical operations are being integrated into the
Pharmaceuticals division.
In the light of government cost containment measures, Novartis intends
to develop new growth platforms such as vaccines (which will reduce
costs through disease prevention) and expand its generic business (so
capitalising on governments' promotion of generics).
This new strategic analysis report Novartis: Performance, Products,
Pipeline and Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts
of key products. The report is updated on a quarterly basis. Buyers of
the web edition receive quarterly reports for a year. Buyers of the
print/pdf editions receive the latest version. All formats are the
same price.
EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position,
company strategy, product and pipeline analysis.
THERAPEUTIC AREA FOCUS
Key product analysis and forecasting
Cardiovascular and Metabolism
Diovan/Co-Diovan (valsartan)
Exforge (amlodipine+valsartan)
Lescol (fluvastatin)
Lotrel (amlodipine+benazepril)
Tekturna (aliskiren)
Oncology/Haematology
Exjade (deferasirox)
Femara (letrozole)
Glivec/Gleevec (imatinib)
Sandostatin (octreotide)
Zometa/Aclasta (zoledronic acid)
Neuroscience
Comtan (entacapone)
Exelon (rivastigmine)
Ritalin/Focalin (methylphenidate)
Stalevo (entacapone)
Trileptal (oxcarbazepine)
Arthritis/Bone
Miacalcic/Miacalcin (synthetic salmon calcitonin)
Prexige (lumiracoxib)
Voltaren/Cataflam (diclofenac sodium)
Gastrointestinal
Zelnorm/Zelmac (tegaserod)
Respiratory/Dermatology
Elidel (pimecrolimus)
Foradil (formoterol fumarate)
Lamisil (terbinafine)
Xolair (omalizumab)
Transplantation/Immunology
Certican (everolimus)
Sandimmun/Neoral (ciclosporin)
Infectious Diseases
Famvir/Denavir (famciclovir)
Sebivo/Tyzeka (telbivudine)
Ophthalmics
Lucentis (ranibizumab)
Visudyne (verteporfin)
OPERATIONAL DATA
A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Infrastructure
Subsidiaries
For more information visit http://www.researchandmarkets.com/reports/c64757
Source: Espicom Business Intelligence
(Comments on this story may be sent to tww.feedback@m2.com)
Newstex ID: MCOM-0001-18828037
Delivered by Newstex LLC
via theFinancials.com
Giuen Media
Advertising Agency
Sales and Promotion
http://giuen.wordpress.com
Associate Website
CWM Online Blog
http://groups.google.com/group/cwm-celebrities
Celebrities Fitness Systems
http://vibe1.redcarpet1.hop.clickbank.net/?tid=MASTER
Online Advertising and Marketing
http://www.adbrite.com/mb/commerce/purchase_form.php?opid=377909&afsid=1
TRADEKEY.COM - Your Key To Global Trade!
A B2B Marketplace for latest products from global Exporters,
Suppliers, Manufacturers and Distributors.